Enrolling by Invitation
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
NCT06419179
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +7 more
- Locations
-
- University Hospital Cologne Cologne, North Rhine-Westphalia, Germany